CD276 and neoplasm: The combined use of ionizable LNPs to deliver mRNA encoding BsAbs, including B7-H3 × CD3, enables in situ antibody production, sustained systemic levels, and improved biodistribution to both tumor sites and secondary lymphoid organs [79].